Approval · Notice of Compliance 34026 · 2024
LUTATHERA: Notice of Compliance 34026
Issued September 16, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34026
- Date
- September 16, 2024
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Radiopharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LUTATHERA | Not yet assigned | — |
Medicinal ingredients
- LUTETIUM (177LU) OXODOTREOTIDE 370 MBQ per ML